毕赤酵母实验操作手册簿
毕赤酵母手册
毕赤酵母表达实验手册作者：Jnuxz 来源：丁香园时间：2007-9-5大肠杆菌表达系统最突出的优点是工艺简单、产量高、周期短、生产成本低。
然而，许多蛋白质在翻译后，需经过翻译后的修饰加工，如磷酸化、糖基化、酰胺化及蛋白酶水解等过程才能转化成活性形式。
大肠杆菌缺少上述加工机制，不适合用于表达结构复杂的蛋白质。
另外，蛋白质的活性还依赖于形成正确的二硫键并折叠成高级结构，在大肠杆菌中表达的蛋白质往往不能进行正确的折叠，是以包含体状态存在。
包含体的形成虽然简化了产物的纯化，但不利于产物的活性，为了得到有活性的蛋白，就需要进行变性溶解及复性等操作，这一过程比较繁琐，同时增加了成本。
大肠杆菌是用得最多、研究最成熟的基因工程表达系统，当前已商业化的基因工程产品大多是通过大肠杆菌表达的，其主要优点是成本低、产量高、易于操作。
但大肠杆菌是原核生物，不具有真核生物的基因表达调控机制和蛋白质的加工修饰能力，其产物往住形成没有活性的包涵体，需要经过变性、复性等处理，才能应用。
近年来，以酵母作为工程菌表达外源蛋白日益引起重视，原因是与大肠杆菌相比，酵母是低等真核生物，除了具有细胞生长快，易于培养，遗传操作简单等原核生物的特点外，又具有真核生物时表达的蛋白质进行正确加工，修饰，合理的空间折叠等功能，非常有利于真核基因的表达，能有效克服大肠杆菌系统缺乏蛋白翻译后加工、修饰的不足。
因此酵母表达系统受到越来越多的重视和利用。
［1］。
同时与大肠杆菌相比，作为单细胞真核生物的酵母菌具有比较完备的基因表达调控机制和对表达产物的加工修饰能力。
酿酒酵母（Saccharomyces.Cerevisiae）在分子遗传学方面被人们的认识最早，也是最先作为外源基因表达的酵母宿主。
1981年酿酒酵母表达了第一个外源基因----干扰素基因［2］，随后又有一系列外源基因在该系统得到表达［3、4、5、6］。
干扰素和胰岛素虽然已经利用酿酒酵母大量生产并被广泛应用，当利用酿酒酵母制备时，实验室的结果很令人鼓舞，但由实验室扩展到工业规模时，其产量迅速下降。
毕赤酵母实验操作手册
毕赤酵母表达实验手册大肠杆菌表达系统最突出的优点是工艺简单、产量高、生产成本低。
然而，许多蛋白质在翻译的修饰加工，如磷酸化、糖基化、酰胺化及蛋白酶水解等过程才能转化成活性形式。
大肠杆菌缺少适合用于表达结构复杂的蛋白质。
另外，蛋白质的活性还依赖于形成正确的二硫键并折叠成高级结表达的蛋白质往往不能进行正确的折叠，是以包含体状态存在。
包含体的形成虽然简化了产物的纯的活性，为了得到有活性的蛋白，就需要进行变性溶解及复性等操作，这一过程比较繁琐，同时增与大肠杆菌相比，酵母是低等真核生物，具有细胞生长快，易于培养，遗传操作简单等原核生物的生物时表达的蛋白质进行正确加工，修饰，合理的空间折叠等功能，非常有利于真核基因的表达，菌系统缺乏蛋白翻泽后加工、修饰的不足。
因此酵母表达系统受到越来越多的重视和利用。
大肠杆菌是用得最多、研究最成熟的基因工程表达系统，当前已商业化的基因工程产品大多是通过其主要优点是成本低、产量高、易于操作。
但大肠杆菌是原核生物，不具有真核生物的基因表达调加工修饰能力，其产物往住形成没有活性的包涵体，需要经过变性、复性等处理，才能应用。
近年程菌表达外源蛋白日益引起重视，主更是因为酵母是单细胞真核生物，不但具有大肠杆菌易操作、化生产的特点，还具有真核生物表达系统基因表达调控和蛋白修饰功能，避免了产物活性低，包涵间题［1］。
与大肠杆菌相比，酵母是单细胞真核生物，具有比较完备的基因表达调控机制和对表达产物的们对酿酒酵母（Saccharomyces.Cerevisiae）分子遗传学方面的认识最早，酿酒酵母也最先作为外宿主．1981年酿酒酵母表达了第一个外源基因一干扰素基因，随后又有一系列外源基因在该系统得素和胰岛素已大量生产并在人群中广泛应用，但很大部分表达由实验室扩展到工业规模时，培养基数的选择压力消失，质粒变得不稳定，拷贝数下降，而大多数外源基因的高效表达需要高拷贝数的量下降。
同时，实验室用培养基复杂而昂贵，采用工业规模能够接受的培养基时，往往导致产量的酵母的局限，人们发展了以甲基营养型酵母（methylotrophic yeast）为代表的第二代酵母表达系甲基营养型酵母包括：Pichia、Candida等．以Pichia.pastoris（毕赤巴斯德酵母）为宿主的外源来发展最为迅速，应用也最为广泛，已利用此系统表达了一系列有重要生物学活性的蛋自质。
毕赤酵母诱导表达实验流程
毕赤酵母诱导表达实验流程下载温馨提示:该文档是我店铺精心编制而成，希望大家下载以后，能够帮助大家解决实际的问题。
文档下载后可定制随意修改，请根据实际需要进行相应的调整和使用，谢谢!并且，本店铺为大家提供各种各样类型的实用资料，如教育随笔、日记赏析、句子摘抄、古诗大全、经典美文、话题作文、工作总结、词语解析、文案摘录、其他资料等等，如想了解不同资料格式和写法，敬请关注!Download tips: This document is carefully compiled by theeditor. I hope that after you download them,they can help yousolve practical problems. The document can be customized andmodified after downloading,please adjust and use it according toactual needs, thank you!In addition, our shop provides you with various types ofpractical materials,such as educational essays, diaryappreciation,sentence excerpts,ancient poems,classic articles,topic composition,work summary,word parsing,copy excerpts,other materials and so on,want to know different data formats andwriting methods,please pay attention!毕赤酵母（Pichia pastoris）是一种常用于外源蛋白表达的真核生物，具有高表达量、高分泌性和易于操作等优点。
毕赤酵母的摇瓶发酵方法[指南]
![毕赤酵母的摇瓶发酵方法[指南]](https://img.taocdn.com/s3/m/3ffac097d5d8d15abe23482fb4daa58da1111c5e.png)
毕赤酵母的摇瓶发酵方法：一、摇瓶发酵方法:毕赤酵母摇瓶发酵方法分为两个阶段，1、酵母菌株生长阶段；2、脂肪酶诱导表达阶段。
1、酵母生长阶段。
准备试剂：1000ml BMGY培养基，1000ml BMMY培养基，10X的甲醇，摇瓶1L（灭菌），温控摇床，50ml离心管（灭菌）。
紫外分光光度计，石英比色皿。
以下所有操作均在超净台内或者无菌条件下完成。
（1）往灭好菌的IL摇瓶中加入100mlBMGY培养基，然后加入约1ml脂肪酶菌株（培养基：菌液=100：1），用透气膜封口（透气，但是细菌不能透过）。
置于温控摇床上，温度调至300C，转速为250-300rpm/min，使酵母生长，OD600=2.0-6.0，时间约为15-24小时。
（2）将发酵液转入50ml离心管，1500g-3000g离心5min。
去掉上清，用BMMY 培养基将菌体浓度稀释至OD600=1.0，约有500ml左右。
将稀释后的发酵液分别加入到1L的药瓶中，每个摇瓶150ml发酵液（绝不能超过200ml）。
（3）将摇瓶置于温控摇床上，温度调至300C，转速为250-300rpm/min，使酵母表达脂肪酶，每24小时加入一次5%的甲醇，使甲醇的终浓度为0.5%。
连续诱导表达48小时。
（4）将发酵液进行12000rpm/min离心5min，取上清（若上清仍混浊，可反复离心）；进行酶活分析和蛋白含量分析。
BMGY培养基的配制（1000ml）：20g蛋白胨（peptone）,10g酵母提取物（Yeast Extract）,加水至700ml；1210C高温灭菌20min。
然后分别在无菌条件下加入10X YNB 100ml，10X 磷酸钾缓冲液（PH6.0）100ml，10X甘油 100ml。
BMMY培养基的配制方法（1000ml）：20g蛋白胨（peptone）,10g酵母提取物,加水至700ml；1210C高温灭菌20min。
然后分别在无菌条件下加入10X YNB 100ml，10X 磷酸钾缓冲液（PH6.0）100ml，10X甲醇 100ml。
毕赤酵母表达(pichia pastoris expression )实验手册(3)
毕赤酵母表达（pichia pastoris expression ）实验手册（3）液体YPD培养基可常温保存；琼脂YPD平板在4℃可保存几个月。
加入Ze ocin 100ug / ml，成为YPDZ培养基，可以4℃条件下保存1～2周。
2.4 YPDS + Zeocin 培养基（Yeast Extract Peptone Dextrose Medi um）：yeast extract 1%peptone 2%dextrose (glucose) 2%sorbitol 1 M+agar 2%+ Zeocin 100 μg/ml不管是液体 YPDS培养基，还是YPDS + Zeocin 培养基，都必须存放4℃条件下，有效期1～2周。
2.5 MGYMinimal Glycerol Medium （最小甘油培养基）（34%YNB；1%甘油；4*10-5%生物素）。
将800ml灭菌水、100ml的 10* YNB母液、2ml的500*B母液和100ml的10*GY母液混匀即可，4℃保存，保存期为2个月。
2.6 MGYHMinimal Glycerol Medium + Histidine （最小甘油培养基 + 0.004%组氨酸）在1000ml的MGY培养基中加入 10ml的100*H母液混匀，4℃保存，保存期为2个月。
2.7 RDRegeneration Dextrose Medium （葡萄糖再生培养基）（含有：1mol/L的山梨醇；2%葡萄糖；1.34%YNB；4*10-5%生物素；0. 005%氨基酸）1. 将186g的山梨醇定容至700ml，高压灭菌；2. 冷却后于45℃水浴；3. 将100ml的10*D、100ml的10*YNB；2ml的500*B；10ml的100*AA等母液和88ml无菌水混匀，预热至45℃后，与步骤2 的山梨醇溶液混合。
4℃保存。
2.8 RDHRegeneration Dextrose Medium + Histidine （葡萄糖再生培养基 + 0.004%组氨酸）在RD培养基配制的第三步中，在加入10ml的100*H母液，同时无菌水的体积减少至78ml即可，其余配制方法与RD相同。
毕赤酵母表达操作手册(精译版)
毕赤酵母多拷贝表达载体试剂盒用于在含多拷贝基因的毕赤酵母菌中表达并分离重组蛋白综述：基本特征：作为真核生物，毕赤酵母具有高等真核表达系统的许多优点：如蛋白加工、折叠、翻译后修饰等。
不仅如此，操作时与E.coli及酿酒酵母同样简单。
它比杆状病毒或哺乳动物组织培养等其它真核表达系统更快捷、简单、廉价，且表达水平更高。
同为酵母，毕赤酵母具有与酿酒酵母相似的分子及遗传操作优点，且它的外源蛋白表达水平是后者的十倍以至百倍。
这些使得毕赤酵母成为非常有用的蛋白表达系统。
与酿酒酵母相似技术：许多技术可以通用：互补转化基因置换基因破坏另外，在酿酒酵母中应用的术语也可用于毕赤酵母。
例如：HIS4基因都编码组氨酸脱氢酶；两者中基因产物有交叉互补；酿酒酵母中的一些野生型基因与毕赤酵母中的突变基因相互补，如HIS4、LEU2、ARG4、TR11、URA3等基因在毕赤酵母中都有各自相互补的突变基因。
毕赤酵母是甲醇营养型酵母：毕赤酵母是甲醇营养型酵母，可利用甲醇作为其唯一碳源。
甲醇代谢的第一步是：醇氧化酶利用氧分子将甲醇氧化为甲醛，还有过氧化氢。
为避免过氧化氢的毒性，甲醛代谢主要在一个特殊的细胞器－过氧化物酶体－里进行，使得有毒的副产物远离细胞其余组分。
由于醇氧化酶与O2的结合率较低，因而毕赤酵母代偿性地产生大量的酶。
而调控产生醇过氧化物酶的启动子也正是驱动外源基因在毕赤酵母中表达的启动子。
两种醇氧化酶蛋白：毕赤酵母中有两个基因编码醇氧化酶－AOX1及AOX2。
细胞中大多数的醇氧化酶是AOX1基因产物。
甲醇可紧密调节、诱导AOX1基因的高水平表达，较典型的是占可溶性蛋白的30%以上。
AOX1基因已被分离，含AOX1启动子的质粒可用来促进编码外源蛋白的目的基因的表达。
AOX2基因与AOX1基因有97%的同源性，但在甲醇中带AOX2基因的菌株比带AOX1基因菌株慢得多，通过这种甲醇利用缓慢表型可分离Muts菌株。
表达：AOX1基因的表达在转录水平受调控。
毕赤酵母实验操作手册
精心整理毕赤酵母表达实验手册大肠杆菌表达系统最突出的优点是工艺简单、产量高、生产成本低。
然而，许多蛋白质在翻译后，需经过翻译后的修饰加工，如磷酸化、糖基化、酰胺化及蛋白酶水解等过程才能转化成活性形式。
大肠杆菌缺少上述加工机制，不适合用于表达结构复杂的蛋白质。
另外，蛋白质的活性还依赖于形成正确的二硫键并折叠成高级核生物表达系统基因表达调控和蛋白修饰功能，避免了产物活性低，包涵体变性、复性等等间题［1］。
与大肠杆菌相比，酵母是单细胞真核生物，具有比较完备的基因表达调控机制和对表达产物的加工修饰能力，人们对酿酒酵母（Saccharomyces.Cerevisiae）分子遗传学方面的认识最早，酿酒酵母也最先作为外源基因表达的酵母宿主．1981年酿酒酵母表达了第一个外源基因一干扰素基因，随后又有一系列外源基因在该系统得到表达。
虽然干扰素和胰岛素已大量生产并在人群中广泛应用，但很大部分表达由实验室扩展到工业规模时，培养基中维特质粒高拷贝数的选择压力消失，质粒变得不稳定，拷贝数下降，而大多数外源基因的高效表达需要高拷贝数的维特，因此引起产量下降。
同时，实验室用培养基复杂而昂贵，采用工业规模能够接受的培养母（一。
⑷毕赤酵母中存在过氧化物酶体，表达的蛋白贮存其中，可免受蛋白酶的降解，而且减少对细胞的毒害作用。
Pichia.pastoris基因表达系统经过近十年发展，已基本成为较完善的外源基因表达系统，具有易于高密度发酵，表达基因稳定整合在宿主基因组中，能使产物有效分泌并适当糖基化，培养方便经济等特点。
利用强效可调控启动子AOX1，已高效表达了HBsAg、TNF、EGF、破伤风毒素C片段、基因工程抗体等多种外源基因，证实该系统为高效、实用、简便，以提高表达量并保持产物生物学活性为突出特征的外源基因表达系统，而且非常适宜子扩大为工业规模［4］。
目前美国FDA已能评价来自该系统的基因工程产品，最近来自该系统的Cephelon制剂已获得FDA批准，所以该系统被认为是安全的．Pichia.pastoris表达系统在生物工程领域将发挥越有中，需带有信号肽序列。
毕赤酵母表达手册
Pichia Expression KitVersion M01110225-0043Pichia Expression KitA Manual of Methods for Expression of Recombinant Proteins in Pichia pastorisCatalog no. K1710-01tech_service@iiINDIVIDUAL PICHIA EXPRESSION KIT LICENSE AGREEMENTThe Pichia Expression Kit is based on the yeast Pichia pastoris. Pichia pastoris was developed into an expression system by scientists at Salk Institute Biotechnology/Industry Associates (SIBIA) for high-level expression of recombinant proteins. All patents for Pichia pastoris and licenses for its use as an expression system are owned by Research Corporation Technologies, Inc. Tucson, Arizona. Invitrogen has an exclusive license to sell the Pichia Expression Kit to scientists for research purposes only, under the terms described below. Use of Pichia pastoris by commercial corporations requires the user to obtain a commercial license as detailed below. Before using the Pichia Expression Kit, please read the following license a greement. If you do not agree to be bound by its terms, contact Invitrogen within 10 days for authorization to return the unused Pichia Expression Kit and to receive a full credit. If you do agree to the terms of this Agreement, please complete the User Registration Card and return it to Invitrogen before using the kit.INDIVIDUAL PICHIA EXPRESSION KIT LICENSE AGREEMENTInvitrogen Corporation (INVITROGEN) grants you a non-exclusive license to use the enclosed Pichia Expression Kit (EXPRESSION KIT) for academic research or for evaluation purposes only. The EXPRESSION KIT is being transferred to you in furtherance of, and reliance on, such license. You may not use the EXPRESSION KIT, or the materials contained therein, for any commercial purpose without a license for such purpose from RESEARCH CORPORATION TECHNOLOGIES, INC., Tucson, Arizona. Commercial purposes include the use in or sale of expressed proteins as a commercial product, or use to facilitate or advance research or development of a commercial product. Commercial entities may conduct their evaluation for one year at which time this license automatically terminates. Commercial entities will be contacted by Research Corporation Technologies during the evaluation period regarding the purchase of a commercial license.Access to the EXPRESSION KIT must be limited solely to those officers, employees and students of your institution who need access thereto in order to perform the above-described research or evaluation. You must inform each of such officer, employee and student of the provisions of this Agreement and require them to agree, in writing, to be bound by the provisions of this Agreement. You may not distribute the EXPRESSION KIT to others, even those within your own institution. You may transfer modified, altered or original material from the EXPRESSION KIT to a third party following notification of INVITROGEN such that the recipient can be licensed. You may not assign, sub-license, rent lease or otherwise transfer this License or any of the rights or obligation hereunder, except as expressly permitted.This License is effective until terminated. You may terminate it at any time by destroying all Pichia expression products in your control. It will also terminate automatically if you fail to comply with the terms and conditions of the Agreement. You shall, upon termination of the License, destroy all Pichia Expression Kits in your control, and so notify INVITROGEN in writing.This License Shall be governed in its interpretation and enforcement by the laws of the State of California.Product User Registration CardPlease complete and return the enclosed Product User Registration Card for each Pichia Expression Kit that you purchase. This will serve as a record of your purchase and registration and will allow Invitrogen to provide you with technical support and manual updates. It will also allow Invitrogen to update you on future developments of and improvements to the Pichia Expression Kit. The agreement outlined above becomes effective upon our receipt of your User Registration Card or 10 days following the sale of the Pichia Expression Kit to you. Use of the kit at any time results in immediate obligation to the terms and conditions stated in this Agreement.Technical ServicesInvitrogen provides Technical Services to all of our registered Pichia Expression Kit users. Please contact us if you need assistance with the Pichia Expression Kit.United States Headquarters:Japanese Headquarters European Headquarters:Invitrogen Corporation1600 Faraday AvenueCarlsbad, CA 92008 USATel: 1 760 603 7200Tel (Toll Free): 1 800 955 6288 Fax: 1 760 602 6500E-mail:tech_service@ Invitrogen Japan K.K.Nihonbashi Hama-Cho Park Bldg. 4F2-35-4, Hama-Cho, NihonbashiTel: 81 3 3663 7972Fax: 81 3 3663 8242E-mail: jpinfo@Invitrogen Ltd3 Fountain DriveInchinnan Business ParkPaisley PA4 9RF, UKTel (Free Phone Orders): 0800 269 210Tel (General Enquiries): 0800 5345 5345Fax: +44 (0) 141 814 6287E-mail: eurotech@iiiivTable of ContentsMaterials (vii)Purchaser Notification (x)Product Qualification (xii)Introduction (1)Overview (1)Experimental Outline (3)Recombination and Integration in Pichia (7)Methods (11)Pichia Strains (11)E. coli Strains (13)Selecting a Pichia Expression Vector (14)pHIL-D2 (16)pPIC3.5 (17)pHIL-S1 (18)pPIC9 (19)Signal Sequence Processing (20)Cloning into the Pichia Expression Vectors (21)Transformation into E. coli (26)Preparation of Transforming DNA (27)Growth of Pichia for Spheroplasting (30)Preparation of Spheroplasts (32)Transformation of Pichia (34)Screening for Mut+ and Mut S Transformants (36)PCR Analysis of Pichia Integrants (40)Expression of Recombinant Pichia Strains (42)Analysis by SDS-Polyacrylamide Gel Electrophoresis (45)Optimization of Pichia Protein Expression (47)Scale-up of Expression (49)Protein Purification and Glycosylation (51)Recipes (53)E. coli Media Recipes (53)Pichia Media Recipes (54)Appendix (59)Electroporation of Pichia (59)PEG 1000 Transformation Method for Pichia (60)Lithium Chloride Transformation Method (61)Total DNA Isolation from Pichia (62)Detection of Multiple Integration Events (63)Procedure for Total RNA Isolation from Pichia (64)β-Galactosidase Assay (65)Technical Service (67)References (69)vviMaterialsKit Contents Box 1: Spheroplast Module. Store at room temperature.Reagent Amount ComponentsSOS media 20 ml 1 M Sorbitol0.3X YPD10 mM CaCl2Sterile Water 2 x 125 ml Autoclaved, deionized waterSE 2 x 125 ml 1 M Sorbitol25 mM EDTA, pH 8.0SCE 2 x 125 ml 1 M Sorbitol10 mM Sodium citrate buffer, pH 5.81 mM EDTA1 M Sorbitol2 x 125 ml --CaS 2 x 60 ml 1 M Sorbitol10 mM Tris-HCl, pH 7.5;10 mM CaCl240% PEG 25 ml 40% (w/v) PEG 3350 (Reagent grade) in waterCaT 25 ml 20 mM Tris-HCl, pH 7.520 mM CaCl2Stab Vials: Pichia and E. coli stabs. Store at +4°C.Phenotype(Pichia only)GenotypeStrain Amountstab his4Mut+GS115 1stab arg4 his4 aox1::ARG4 Mut S, Arg+KM71 1GS115 Albumin 1 stab HIS4Mut SGS115 β-Gal 1 stab HIS4Mut+stab F´ {pro AB, lac I q, lac Z∆M15, Tn10 (Tet R)} mcr A,TOP10F´ 1∆(mrr-hsd RMS-mcr BC), φ80lac Z∆M15, ∆lac X74,deo R, rec A1, ara D139, ∆(ara-leu)7697, gal U,gal K, rps L (Str R), end A1, nup G λ-.Box 2: Spheroplast Module. Store at -20°C.ComponentsReagent AmountZymolyase 10 x 20 µl 3 mg/ml Zymolyase in water(100,000 units/g lytic activity)1 M DTT 10 x 1 ml 1 M dithiothreitol in watercontinued on next pageviiKit Contents,continuedVector Box. Store at -20°C.Reagent DescriptionpHIL-D210 µg, lyophilized in TE, pH 8.0Vector for intracellular expression in PichiapPIC3.510 µg, lyophilized in TE, pH 8.0Vector for intracellular expression in PichiapHIL-S110 µg, lyophilized in TE, pH 8.0 Vector for secreted expression in Pichia. Uses the PHO1 signal sequencepPIC910 µg, lyophilized in TE, pH 8.0 Vector for secreted expression in Pichia. Uses the α-factor signal sequencePrimer Box. Store at -20°C.5´ AOX1 sequencing primer2 µg (312 pmoles), lyophilized5´-GACTGGTTCCAATTGACAAGC-3´3´ AOX1 sequencing primer2 µg (314 pmoles), lyophilized5´-GCAAATGGCATTCTGACATCC-3´α-Factor sequencing primer2 µg (315 pmoles), lyophilized5´-TACTATTGCCAGCATTGCTGC-3´Media The following prepackaged media is included for your convenience. Instructions for use are provided on the package.Media Amount Yield YP Base Medium 2 pouches 2 liters of YP mediumYP Base Agar Medium 2 pouches 2 liters of YP mediumYeast Nitrogen Base 1 pouch 500 ml of 10X YNBFor transformation of Pichia by spheroplasting, the Pichia Spheroplast Module isavailable separately from Invitrogen (see below for ordering information).Product Reactions or Amount Catalog no.Pichia Spheroplast Module 10 spheroplast preparations(50 transformations)K1720-01continued on next pageviiiRequired Equip-ment and Supplies (not provided) • 30°C rotary shaking incubator• Water baths capable of 37°C, 45°C, and 100°C• Centrifuge suitable for 50 ml conical tubes (floor or table-top)• Baffled culture flasks with metal covers (50 ml, 250 ml, 500 ml, 1000 ml, and 3 L)• 50 ml sterile, conical tubes• 6 ml and 15 ml sterile snap-top tubes (Falcon 2059 or similar)• UVSpectrophotometer• Mini agarose gel apparatus and buffers• Polyacrylamide Gel Electrophoresis apparatus and buffers• Media for transformation, growth, screening, and expression (see Recipes, pages 53-58) • 5% SDS solution (10 ml per transformation)• Sterile cheesecloth or gauze• Breaking Buffer (see Recipes, page 58)• Acid-washed glass beads (available from Sigma)• Replica-plating equipment (optional)• BeadBreaker™ (optional)ixPurchaser NotificationIntroduction The Pichia Expression Kit is based on the yeast Pichia pastoris. Pichia pastoris wasdeveloped into an expression system by scientists at Salk Institute Biotechnology/ IndustryAssociates (SIBIA) and Phillips Petroleum for high-level expression of recombinantproteins. All patents for Pichia pastoris and licenses for its use as an expression system areowned by Research Corporation Technologies (RCT), Inc., Tucson, Arizona. Forinformation on commercial licenses, please see page x.The Nature of the Invitrogen License Invitrogen has an exclusive license to sell the Pichia Expression Kit to scientists for research purposes only, under the terms described below. Use of Pichia pastoris by commercial entities for any commercial purpose requires the user to obtain a commercial license as detailed below. Before using the Pichia Expression Kit, please read the following license agreement. If you do not agree to be bound by its terms, contact Invitrogen within 10 days for authorization to return the unused Pichia Expression Kit and to receive a full credit. If you do agree to the terms of this license agreement, please complete the User Registration Card and return it to Invitrogen before using the kit.Pichia pastoris Patents Pichia pastoris is covered by one or more of the following U.S. patents and corresponding foreign patents owned and licensed by Research Corporation Technologies:4,683,293 4,808,537 4,812,405 4,818,700 4,837,148 4,855,231 4,857,467 4,879,231 4,882,279 4,885,242 4,895,800 4,929,555 5,002,876 5,004,688 5,032,516 5,122,465 5,135,868 5,166,329Individual Pichia Expression Kit License Agreement Invitrogen Corporation ("Invitrogen") grants you a non-exclusive license to use the enclosed Pichia Expression Kit ("Expression Kit") for academic research or for evaluation purposes only. The Expression Kit is being transferred to you in furtherance of, and reliance on, such license. You may not use the Expression Kit, or the materials contained therein, for any commercial purpose without a license for such purpose from Research Corporation Technologies, Inc., Tucson, Arizona.Definition of Commercial Purpose Commercial purposes include:(a) any use of Expression Products in a Commercial Product(b) any use of Expression Products in the manufacture of a Commercial Product(c) any sale of Expression Products(d) any use of Expression Products or the Expression Kit to facilitate or advanceresearch or development of a Commercial Product(e) any use of Expression Products or the Expression Kit to facilitate or advance anyresearch or development program the results of which will be applied to thedevelopment of Commercial Products"Expression Products" means products expressed with the Expression Kit, or with the use of any vectors or host strains in the Expression Kit. "Commercial Product" means any product intended for sale or commercial use.Commercial entities may conduct their evaluation for one year at which time this license automatically terminates. Research Corporation Technologies will contact commercial entities during the evaluation period regarding their desire for a commercial license.continued on next pagexPurchaser Notification, continuedIndividual Responsibilities Access to the Expression Kit must be limited solely to those officers, employees and students of your institution who need access to perform the above-described research or evaluation. You must inform each such officer, employee and student of the provisions of this license agreement and require them to agree, in writing, to be bound by the provisions of this license agreement. You may not distribute neither the Expression Kit nor the vectors or host strains contained in it to others, even to those within your own institution. You may only transfer modified, altered, or original material from the Expression Kit to a third party following written notification of, and written approval from, Invitrogen so that the recipient can be licensed. You may not assign, sub-license, rent, lease or otherwise transfer this license agreement or any of the rights or obligation thereunder, except as expressly permitted by Invitrogen and RCT.Termination of License This license agreement is effective until terminated. You may terminate it at any time by destroying all Pichia expression products in your control. It will also terminate auto-matically if you fail to comply with the terms and conditions of the license agreement. You shall, upon termination of the license agreement, destroy all Pichia Expression Kits in your control, and so notify Invitrogen in writing.This License shall be governed in its interpretation and enforcement by the laws of the State of California.Contact for Commercial Licensing Bennett Cohen, Ph.D.Research Corporation Technologies 101 North Wilmot Road, Suite 600 Tucson, Arizona 85711-3335 Phone: (520) 748-4400Fax: (520)748-0025User Registration Card Please complete and return the enclosed User Registration Card for each PichiaExpression Kit that you purchase. This will serve as a record of your purchase and regis-tration and will allow Invitrogen to provide you with technical support and manualupdates. It will also allow Invitrogen to update you on future developments and improve-ments to the Pichia Expression Kit. The agreement outlined above becomes effectiveupon our receipt of your User Registration Card or 10 days following the sale of thePichia Expression Kit to you. Use of the kit at any time results in immediate obligation tothe terms and conditions stated in this license agreement.xiProduct QualificationIntroduction This section describes the criteria used to qualify the components in the PichiaExpression Kit.Vectors All expression vectors are qualified by restriction enzyme digestion. Restriction digests must demonstrate the correct banding pattern when electrophoresed on an agarose gel.Spheroplast Reagents The spheroplast reagents are qualified by spheroplast preparation of GS115 following the protocol provided in the Pichia Expression Kit manual. At least 70% of the Pichia pastoris cells must form spheroplasts in 30 minutes or less.Pichia Strains The Pichia strains are by demonstrating viability of the culture. Single colonies should arise within 48 hours after streaking on YPD medium from the stabPrimers Sequencing primers are lot tested by automated DNA sequencing experiments.Buffers andSolutionsAll buffers and solutions are extensively tested for sterility.Media All Pichia growth and expression media are qualified by growing the GS115 Pichiastrain.xiiIntroductionOverviewReview Articles The information presented here is designed to give you a concise overview of the Pichia pastoris expression system. It is by no means exhaustive. For further information, pleaseread the articles cited in the text along with recent review articles (Buckholz and Gleeson,1991; Cregg et al., 1993; Sreekrishna et al., 1988; Wegner, 1990). A general review offoreign gene expression in yeast is also available (Romanos et al., 1992).General Characteristics of Pichia pastoris As a eukaryote, Pichia pastoris has many of the advantages of higher eukaryotic expression systems such as protein processing, protein folding, and posttranslational modification, while being as easy to manipulate as E. coli or Saccharomyces cerevisiae. It is faster, easier, and less expensive to use than other eukaryotic expression systems such as baculovirus or mammalian tissue culture, and generally gives higher expression levels. As a yeast, it shares the advantages of molecular and genetic manipulations with Saccharomyces, and has the added advantage of 10- to 100-fold higher heterologous protein expression levels. These features make Pichia very useful as a protein expression system.Similarity to Saccharomyces Many of the techniques developed for Saccharomyces may be applied to Pichia including: • transformation by complementation• genedisruption• genereplacementIn addition, the genetic nomenclature used for Saccharomyces has been applied to Pichia. For example, the HIS4 gene in both Saccharomyces and Pichia encodes histidinol dehydrogenase. There is also cross-complementation between gene products in both Saccharomyces and Pichia. Several wild-type genes from Saccharomyces complement comparable mutant genes in Pichia. Genes such as HIS4, LEU2, ARG4, TRP1, and URA3 all complement their respective mutant genes in Pichia.Pichia pastoris as a Methylotrophic Yeast Pichia pastoris is a methylotrophic yeast, capable of metabolizing methanol as its sole carbon source. The first step in the metabolism of methanol is the oxidation of methanol to formaldehyde using molecular oxygen by the enzyme alcohol oxidase. This reaction generates both formaldehyde and hydrogen peroxide. To avoid hydrogen peroxide toxicity, methanol metabolism takes place within a specialized cell organelle called the peroxisome, which sequesters toxic by-products from the rest of the cell. Alcohol oxidase has a poor affinity for O2, and Pichia pastoris compensates by generating large amounts of the enzyme. The promoter regulating the production of alcohol oxidase drives heterologous protein expression in Pichia.Two Alcohol Oxidase Proteins The AOX1 and AOX2 genes code for alcohol oxidase in Pichia pastoris. The AOX1 gene product accounts for the majority of alcohol oxidase activity in the cell. Expression of the AOX1 gene is tightly regulated and induced by methanol to high levels, typically > 30% ofthe total soluble protein in cells grown with methanol as the carbon source. The AOX1 gene has been isolated and the AOX1 promoter is used to drive expression of the gene of interest (Ellis et al., 1985; Koutz et al., 1989; Tschopp et al., 1987a). While AOX2 is about 97% homologous to AOX1, growth on methanol is much slower than with AOX1. This slowgrowth allows isolation of Mut S strains (aox1) (Cregg et al., 1989; Koutz et al., 1989).continued on next page1Overview, continuedExpression Expression of the AOX1 gene is controlled at the level of transcription. In methanol-grown cells approximately 5% of the polyA+ RNA is from the AOX1 gene. The regulation of theAOX1 gene is a two step process: a repression/derepression mechanism plus an inductionmechanism (e.g. GAL1 gene in Saccharomyces (Johnston, 1987)). Briefly, growth onglucose represses transcription, even in the presence of the inducer methanol. For thisreason, growth on glycerol is recommended for optimal induction with methanol. Pleasenote that growth on glycerol (derepression) is not sufficient to generate even minute levelsof expression from the AOX1 gene. The inducer, methanol, is necessary for detectablelevels of AOX1 expression (Ellis et al., 1985; Koutz et al., 1989; Tschopp et al., 1987a).Phenotype of aox1 mutants Loss of the AOX1 gene, and thus a loss of most of the cell's alcohol oxidase activity, results in a strain that is phenotypically Mut S (Methanol utilization slow). This has in the past been referred to as Mut. The Mut S designation has been chosen to accurately describe the phenotype of these mutants. This results in a reduction in the cells' ability to metabolize methanol. The cells, therefore, exhibit poor growth on methanol medium. Mut+ (Methanol utilization plus) refers to the wild type ability of strains to metabolize methanol as the sole carbon source. These two phenotypes are used when evaluating Pichia transformants for integration of your gene (Experimental Outline, page 3).Intracellular and Secretory Protein Expression Heterologous expression in Pichia can be either intracellular or secreted. Secretion requires the presence of a signal sequence on the expressed protein to target it to the secretory pathway. While several different secretion signal sequences have been used successfully, including the native secretion signal present on some heterologous proteins, success has been variable. The secretion signal sequence from the Saccharomyces cerevisiaeα factor prepro peptide has been used most successfully (Cregg et al., 1993; Scorer et al., 1993).The major advantage of expressing heterologous proteins as secreted proteins is that Pichia pastoris secretes very low levels of native proteins. That, combined with the very low amount of protein in the minimal Pichia growth medium, means that the secreted heterologous protein comprises the vast majority of the total protein in the medium and serves as the first step in purification of the protein (Barr et al., 1992). Note: If there are recognized glycosylation sites (Asn-X-Ser/Thr) in your protein's primary sequence, glycosylation may occur at these sites.Posttranslational Modifications In comparison to Saccharomyces cerevisiae, Pichia may have an advantage in the glyco-sylation of secreted proteins because it may not hyperglycosylate. Both Saccharomyces cerevisiae and Pichia pastoris have a majority of N-linked glycosylation of the high-mannose type; however, the length of the oligosaccharide chains added posttranslationally to proteins in Pichia (average 8-14 mannose residues per side chain) is much shorter than those in S. cerevisiae (50-150 mannose residues) (Grinna and Tschopp, 1989; Tschopp et al., 1987b). Very little O-linked glycosylation has been observed in Pichia.In addition, Saccharomyces cerevisiae core oligosaccharides have terminal α1,3 glycan linkages whereas Pichia pastoris does not. It is believed that the α1,3 glycan linkages in glycosylated proteins produced from Saccharomyces cerevisiae are primarily responsible for the hyper-antigenic nature of these proteins making them particularly unsuitable for therapeutic use. Although not proven, this is predicted to be less of a problem for glycoproteins generated in Pichia pastoris, because it may resemble the glycoprotein structure of higher eukaryotes (Cregg et al., 1993).2Experimental OutlineSelection of Vector and Cloning To utilize the strong, highly inducible P AOX1 promoter for expression of your protein, four expression vectors are included in this kit. pHIL-D2 and pPIC3.5 are used for intracellular expression while pHIL-S1 and pPIC9 are used for secreted expression (see pages 14-19 for more information). Before cloning your insert, you must...• decide whether you want intracellular or secreted expression.• analyze your insert for the following restriction sites: Sac I, Stu I, Sal I, Not I, and Bgl II. These sites are recommended for linearizing your construct prior to Pichiatransformation. If your insert has all of these sites, see pages 28-29 for alternate sites.Transformation and IntegrationTwo different phenotypic classes of His+ recombinant strains can be generated: Mut+ and Mut S. Mut S refers to the "Methanol utilization slow" phenotype caused by the loss of alcohol oxidase activity encoded by the AOX1 gene. A strain with a Mut S phenotype has a mutant aox1 locus, but is wild type for AOX2. This results in a slow growth phenotype on methanol medium. Transformation of strain GS115 can yield both classes of transformants, His+ Mut+ and His+Mut S, while KM71 yields only His+ Mut S since the strain itself is Mut S. Both Mut+ and Mut S recombinants are useful to have as one phenotype may favor better expression of your protein than the other. Due to clonal variation, you should test 6-10 recombinants per phenotype. There is no way to predict beforehand which construct or isolate will better express your protein. We strongly recommend that you analyze Pichia recombinants by PCR to confirm integration of your construct (see page 40).Once you have successfully cloned your gene, you will then linearize your plasmid to stimulate recombination when the plasmid is transformed into Pichia. The table below describes the types of recombinants you will get by selective digestion of your plasmid. RestrictionEnzymeIntegration Event GS115 Phenotype KM71 PhenotypeSal I or Stu I Insertion at his4His+ Mut+ His+ Mut SSac I Insertion at 5´AOX1 regionHis+ Mut+ His+ Mut SNot I or Bgl II Replacement atAOX1 locusHis+ Mut SHis+ Mut+His+ Mut S (notrecommended, see page 11)Expression and Scale-up After confirming your Pichia recombinants by PCR, you will test expression of both His+Mut+ and His+ Mut S recombinants. This will involve growing a small culture of each recombinant, inducing with methanol, and taking time points. If looking for intracellular expression, analyze the cell pellet from each time point by SDS polyacrylamide gel electrophoresis (SDS-PAGE). If looking for secreted expression, analyze both the cellpellet and supernatant from each time point. We recommend that you analyze your SDS-PAGE gels by both Coomassie staining and Western blot, if you have an antibody to your protein. We also suggest checking for protein activity by assay, if one is available. Not all proteins express to the level of grams per liter, so it is advisable to check by Western blotor activity assay, and not just by Coomassie staining of SDS-PAGE gels for production of your protein.Choose the Pichia recombinant strain that best expresses your protein and optimizeinduction based on the suggestions on pages 47-48. Once expression is optimized, scale-up your expression protocol to produce more protein.continued on next page3。
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
毕赤酵母表达实验手册大肠杆菌表达系统最突出的优点是工艺简单、产量高、生产成本低。
然而，许多蛋白质在翻译后，需经过翻译后的修饰加工，如磷酸化、糖基化、酰胺化及蛋白酶水解等过程才能转化成活性形式。
大肠杆菌缺少上述加工机制，不适合用于表达结构复杂的蛋白质。
另外，蛋白质的活性还依赖于形成正确的二硫键并折叠成高级结构，在大肠杆菌中表达的蛋白质往往不能进行正确的折叠，是以包含体状态存在。
包含体的形成虽然简化了产物的纯化，但不利于产物的活性，为了得到有活性的蛋白，就需要进行变性溶解及复性等操作，这一过程比较繁琐，同时增加了成本。
与大肠杆菌相比，酵母是低等真核生物，具有细胞生长快，易于培养，遗传操作简单等原核生物的特点，又具有真核生物时表达的蛋白质进行正确加工，修饰，合理的空间折叠等功能，非常有利于真核基因的表达，能有效克服大肠杆菌系统缺乏蛋白翻泽后加工、修饰的不足。
因此酵母表达系统受到越来越多的重视和利用。
大肠杆菌是用得最多、研究最成熟的基因工程表达系统，当前已商业化的基因工程产品大多是通过大肠杆菌表达的，其主要优点是成本低、产量高、易于操作。
但大肠杆菌是原核生物，不具有真核生物的基因表达调控机制和蛋白质的加工修饰能力，其产物往住形成没有活性的包涵体，需要经过变性、复性等处理，才能应用。
近年来，以酵母作为工程菌表达外源蛋白日益引起重视，主更是因为酵母是单细胞真核生物，不但具有大肠杆菌易操作、繁殖快、易于工业化生产的特点，还具有真核生物表达系统基因表达调控和蛋白修饰功能，避免了产物活性低，包涵体变性、复性等等间题［1］。
与大肠杆菌相比，酵母是单细胞真核生物，具有比较完备的基因表达调控机制和对表达产物的加工修饰能力，人们对酿酒酵母（Saccharomyces.Cerevisiae）分子遗传学方面的认识最早，酿酒酵母也最先作为外源基因表达的酵母宿主．1981年酿酒酵母表达了第一个外源基因一干扰素基因，随后又有一系列外源基因在该系统得到表达。
虽然干扰素和胰岛素已大量生产并在人群中广泛应用，但很大部分表达由实验室扩展到工业规模时，培养基中维特质粒高拷贝数的选择压力消失，质粒变得不稳定，拷贝数下降，而大多数外源基因的高效表达需要高拷贝数的维特，因此引起产量下降。
同时，实验室用培养基复杂而昂贵，采用工业规模能够接受的培养基时，往往导致产量的下降。
为克服酿酒酵母的局限，人们发展了以甲基营养型酵母（methylotrophic yeast）为代表的第二代酵母表达系统［2］。
甲基营养型酵母包括：Pichia、Candida等．以Pichia.pastoris（毕赤巴斯德酵母）为宿主的外源基因表达系统近年来发展最为迅速，应用也最为广泛，已利用此系统表达了一系列有重要生物学活性的蛋自质。
毕赤酵母系统的广泛应用，原因在于该系统除了具有一般酵母所具有的特点外，还有以下几个优点［1、2、3］；⑴具有醇氧化酶AOX1基因启动子，这是目前最强，调控机理最严格的启动子之一。
⑵表达质粒能在基因组的特定位点以单拷贝或多拷贝的形式稳定整合。
（即同源重组）⑶菌株易于进行高密度发酵，外源蛋白表达量高。
⑷毕赤酵母中存在过氧化物酶体，表达的蛋白贮存其中，可免受蛋白酶的降解，而且减少对细胞的毒害作用。
Pichia.pastoris基因表达系统经过近十年发展，已基本成为较完善的外源基因表达系统，具有易于高密度发酵，表达基因稳定整合在宿主基因组中，能使产物有效分泌并适当糖基化，培养方便经济等特点。
利用强效可调控启动子AOX1，已高效表达了HBsAg、TNF、EGF、破伤风毒素C片段、基因工程抗体等多种外源基因，证实该系统为高效、实用、简便，以提高表达量并保持产物生物学活性为突出特征的外源基因表达系统，而且非常适宜子扩大为工业规模［4］。
目前美国FDA 已能评价来自该系统的基因工程产品，最近来自该系统的Cephelon制剂已获得FDA批准，所以该系统被认为是安全的．Pichia.pastoris表达系统在生物工程领域将发挥越来越重要的作用，促进更多外源基因在该系统的高效表达，提供更为广泛的基因工程产品［2、3］。
近年来，Invitrogon公司开发了毕赤酵母表达系统的系列产品，短短几年已经有300多种外源蛋自在该系统得到有效表达，被认为是目前最有效的酵母表达系统。
毕赤酵母宿主菌常用的有GS115和KM71两种，都具有HIS4营养缺陷标记。
其中，GS115茵株具有AOX1基因，是Mut＋，即甲醇利用正常型；而KM71菌株的AOX1位点被ARG4基因插入，表型为Muts，即甲醇利用缓慢型，两种菌株都适用于一般的酵母转化方法。
Pichia.pastoris酵母菌体无天然质粒，所以表达载体需与宿主染色体发生同源重组，将外源基因表达框架整合于染色体中以实现外源基因的表达［5］．包括启动子、外源基因克隆位点、终止序列、筛选标记等。
表达载体都是穿梭质粒，先在大肠杆菌复制扩增，然后被导入宿主酵母细胞。
为使产物分泌胞外，表达载体还需带有信号肽序列。
毕赤酵母表达系统有多种分泌型表达质粒，有许多蛋白在毕赤酵母得到了高效分泌表达。
胞外表达需要在外源蛋白的N末端加上一段信号肽序列，引导重组蛋白进入分泌途径，可使蛋白蛋白质在分泌到胞外之后获得准确的构型。
毕赤酵母对外源蛋白自身的信号序列识别能力差，在本试验中所使用pPICZαA质粒，其信号肽来自酿酒酵母的α-交配因子（α-factor），能很好的达到以上的要求。
并且作为新一代的毕赤酵母分泌表达质粒，它还拥有一个特点是其具有Zeocin抗性标记基因，给我们筛选转化子的工作带来很大的便利［1、2］。
pPICZαA质粒是作为新一代的毕赤酵母分泌表达质粒，它的主要特点简介如下：⑴具有强效可调控启动子AOX1（alcohol oxidase，醇氧化酶）；⑵具有Zeocin抗性筛选标记基因，重组转化子可直接用Zeocin进行筛选，即在YPDZ平板上生长的转化子中，100％都有外源基因的整合，大大简化了重组转化酵母的筛选过程［5］。
在操作过程中，Zeocin也可用来筛选含表达载体pPICZαA的大肠杆菌转化子，不必另外使用Amp，经济而又简便；。
⑶在表达载体A0X1 5’端启动子序列下游，有供外源基因插入的多克隆位点，多克隆位点下游有A0X1 3’端终止序列；⑷分泌效率强的信号肽α-factor.Invitrogen公司开发的毕赤酵母表达系统的系列产品作为目前被应用为最为广泛的酵母表达系统，其主要的优点有：醇氧化酶可调控的强启动子，能高密度发酵，重组蛋白表达量高。
外源基因整合在酵母基因组上，可以稳定存在。
同时，高效分泌表达质粒能将外源蛋白表达后，进行翻译后加工处理，将外源蛋白分泌到细胞外，不但提高表达蛋白的活性，而且，有利于产物的纯化。
一．毕赤酵母表达常用溶液及缓冲液的配制1．1 各种母液的配制10*YNB （含有硫酸铵、无氨基酸的13.4%酵母基础氮源培养基）4℃保存。
34g 酵母基础氮源培养基（无硫酸铵）+100g硫酸铵，溶于1000ml水中，过滤除菌。
500*B （0.02%生物素Biotin）4℃保存保存期为1年。
20mg的生物素溶于100ml水中，过滤除菌。
100*H （0.4%Histidine 组氨酸）4℃保存保存期为1年。
400mg的L-组氨酸溶于100ml水中，（加热至50℃以促进溶解），过滤除菌。
10*D （20%Dextrose 葡萄糖）保存期为1年。
200g葡萄糖溶于1000ml 水中，灭菌15min或过滤除菌。
10*M （5%Methanol 甲醇）保存期为2个月。
将5ml的甲醇与95ml水混匀，过滤除菌。
10*GY （10%Glycerol 甘油）保存期为1年以上。
将100ml甘油和900ml 水混匀后，高压灭菌或过滤除菌。
100*AA （0.5% of each Amino Acid，各种氨基酸）4℃保存保存期为1年。
分别将500mg的L-谷氨酸、L-蛋氨酸、L-赖氨酸、L-亮氨酸和L-异亮氨酸溶于100ml水中，过滤除菌。
1M 磷酸钾溶液（potassium phosphate buffer，pH6.0），将1mol/L的K2HPO4溶液132ml与1mol/L的KH2PO4溶液868ml混匀，其pH为6.0，如需调节pH，则使用磷酸和氢氧化钾调节pH。
1.2 常用溶液及缓冲夜1.2.1 碱裂解法抽提质粒DNA所用溶液：溶液Ⅰ：50mmol / L glucose，100mmol / L EDTA，25mmol / L Tris－HCI (pH 8.0)溶液Ⅱ：0.2mol／L NaOH，1％SDS（临用时配制）溶液Ⅲ：29.44g KAc，11.5ml Acetic acid，加ddH2O至100 ml。
4℃保存。
1.2.2 10% 甘油（Glycerol）：将100ml甘油和900ml水混匀后，高压灭菌或过滤除菌。
保存期为1年以上。
1.2.3 Rnase-H2O：1ul Rnase 加入1ml 灭菌dd H2O。
4℃保存。
1.2.4 TE缓冲液：10mmol / Tris-CI（pH 8．0），lmmol / L EDTA（pH 8.0）1.2.5 STE缓冲液：0.1mol / L, 10mmol / L Tris-HCl (pH 8.0), 1mmol / L EDTA (pH 8.0)1.2.6 SCE缓冲液：1mol / L Sorbitol (山梨醇), 10mmol / L 柠檬酸钠，10mmol / L EDTA 1.2.7 1M potassium phosphate buffer （pH 6.0）：132 ml 1M K2HPO4868 ml 1M KH2PO41.2.8 50X TAE 琼脂糖凝胶电泳缓冲液，pH 8.0（1L）：242 g Tris57.1 ml Acetic Acid37.2 g EDTA二．毕赤酵母表达的培养基配制［5］2.1 LB（Luria－Bertani）培养基：Trypton l％Yeast Extract 0.5％NaCl l％PH 7.0制作平板时加入2％琼脂粉。
121℃高压灭菌20min。
可于室温保存。
用于培养pPICZαA原核宿主菌TOP10F’时可加入Zeocin 25ug / ml。
2.2 LLB（Low Salt LB）培养基：Trypton l％Yeast Extract 0.5％NaCl 0.5％PH 7.0制作平板时加入2％琼脂粉。
121℃高压灭菌20min。
可于室温保存数月。
用于培养pPICZαA原核宿主菌TOP10F’时，加入Zeocin 25ug / ml，可以4℃条件下保存1～2周。
2.3 YPD （又称YEPD）Yeast Extract Peptone Dextrose Medium，（Yeast Extract Peptone Dextrose Medium，酵母浸出粉/胰蛋白胨/右旋葡萄糖培养基）Trypton 2%dextrose (glucose) 2%+agar 2%+Zeocin 100 µg/ml液体YPD培养基可常温保存；琼脂YPD平板在4℃可保存几个月。